Daniel Kuritzkes

Daniel R. Kuritzkes, MD received his BS and MS degrees in Molecular Biophysics and Biochemistry from Yale University, and his MD from Harvard Medical School. He completed his clinical and research training in internal medicine and infectious disease at Massachusetts General Hospital and was a visiting scientist at the Whitehead Institute for Biomedical Research before joining the faculty at the University of Colorado Health Sciences Center. Dr. Kuritzkes returned to Harvard Medical School in 2002, where he is Professor of Medicine and Chief, Division of Infectious Diseases at Brigham and Women’s Hospital.

Dr. Kuritzkes has published extensively on antiretroviral therapy and drug resistance in HIV-1 infection. He has chaired several multicenter studies of HIV therapy and is a member of the Department of Health and Human Services panel on guidelines for antiretroviral therapy. He has served on numerous NIH committees and editorial boards, and previously served as Chair of the HIV Medicine Association Board of Directors. He currently serves as Principal Investigator and Chair of the AIDS Clinical Trials Group, and as an Associate Editor of the Journal of Infectious Diseases. His research interests focus on antiretroviral therapy, drug resistance and HIV eradication.

Publications

1. Li JZ, Paredes R, Ribaudo H, Svarovskaia ES, Metzner KJ, Kozal MJ, Huppler Hulsiek K, Balduin M, Jakobsen MR, Geretti AM, Thiebaut R, Ostergaard L, Masquelier B, Johnson JA, Miller MD, Kuritzkes DR. Minority HIV-1 Drug Resistance Mutations and the Risk of NNRTI-based Antiretroviral Treatment Failure: A Systematic Review and Pooled Analysis. JAMA 2011, 305:1327-35.

2. Hu X, Kuritzkes DR. Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1. J Virol 2011; 85:11309-14.

3. Putcharoen O, Lee SH, Henrich TJ, Hu Z, Vanichanan J, Coakley E, Greaves W, Kuritzkes DR, Tsibris AMN. HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that correct in the presence of drug. J Virol 2012; 86:1119-28.

4. Tsibris AMN, Hu Z, Paredes R, Leopold KE, Putcharoen O, Schure AL, Mazur N, Coakley E, Su Z, Gulick RM, Kuritzkes DR. Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures. J Virol 2012; 86:6416-26.

5. Lin NH, Becerril C, Giguel F, Novitsky V, Moyo S, Makhema J, Essex M, Lockman S, Kuritzkes DR, Sagar M. Env sequence determinants in CXCR4-using human immunodeficiency virus type-1 subtype C. Virology 2012; 433:296-307.

6. Henrich TJ, Gallien S, Li JZ, Pereyra F, Kuritzkes DR. Low-level detection and quantitation of cellular HIV-1 DNA and 2-LTR circles using droplet digital PCR. J Virol Methods 2012; 186:68-72.

7. Henrich TJ, Hu Z, Li JZ, Sciaranghella G, Busch MP, Keating SM, Gallien S, Lin NH, Giguel F, Lavoie L, Ho VT, Armand P, Soiffer RJ, Sagar M, LaCasce AS, Kuritzkes DR. Long-term reduction in peripheral blood HIV-1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis 2013 Mar 4 [Epub ahead of print].